WO2006041897A3 - Vecteurs chimériques - Google Patents

Vecteurs chimériques Download PDF

Info

Publication number
WO2006041897A3
WO2006041897A3 PCT/US2005/035785 US2005035785W WO2006041897A3 WO 2006041897 A3 WO2006041897 A3 WO 2006041897A3 US 2005035785 W US2005035785 W US 2005035785W WO 2006041897 A3 WO2006041897 A3 WO 2006041897A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric vectors
vectors
relates
expressing
chimeric
Prior art date
Application number
PCT/US2005/035785
Other languages
English (en)
Other versions
WO2006041897A2 (fr
Inventor
Jiansheng Yao
Sheena May Loosmore
Jean-Christophe Franc Audonnet
Original Assignee
Merial Ltd
Jiansheng Yao
Sheena May Loosmore
Jean-Christophe Franc Audonnet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Jiansheng Yao, Sheena May Loosmore, Jean-Christophe Franc Audonnet filed Critical Merial Ltd
Priority to MX2007004168A priority Critical patent/MX2007004168A/es
Priority to BRPI0516576 priority patent/BRPI0516576C8/pt
Priority to CA2583147A priority patent/CA2583147C/fr
Priority to EP05809870.8A priority patent/EP1809337B1/fr
Publication of WO2006041897A2 publication Critical patent/WO2006041897A2/fr
Publication of WO2006041897A3 publication Critical patent/WO2006041897A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des vecteurs chimériques. Plus spécifiquement, cette invention a trait à des vecteurs de poxvirus recombinants et à des virus capables d'exprimer un réplicon d'ARN d'alphavirus exprimant une séquence hétérologue d'intérêt.
PCT/US2005/035785 2004-10-05 2005-10-04 Vecteurs chimériques WO2006041897A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2007004168A MX2007004168A (es) 2004-10-05 2005-10-04 Vectores quimericos.
BRPI0516576 BRPI0516576C8 (pt) 2004-10-05 2005-10-04 Vetores quiméricos
CA2583147A CA2583147C (fr) 2004-10-05 2005-10-04 Vecteurs chimeriques
EP05809870.8A EP1809337B1 (fr) 2004-10-05 2005-10-04 Vecteurs chimeriques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/958,267 2004-10-05
US10/958,267 US7998733B2 (en) 2004-10-05 2004-10-05 Chimeric vectors

Publications (2)

Publication Number Publication Date
WO2006041897A2 WO2006041897A2 (fr) 2006-04-20
WO2006041897A3 true WO2006041897A3 (fr) 2006-12-21

Family

ID=36126051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035785 WO2006041897A2 (fr) 2004-10-05 2005-10-04 Vecteurs chimériques

Country Status (6)

Country Link
US (1) US7998733B2 (fr)
EP (1) EP1809337B1 (fr)
BR (1) BRPI0516576C8 (fr)
CA (1) CA2583147C (fr)
MX (1) MX2007004168A (fr)
WO (1) WO2006041897A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065476A1 (fr) * 2007-11-30 2009-06-03 Institut Pasteur Essai de criblage à base de cellules de mammifères pour l'identification d'inhibiteurs des alphavirus
MX351642B (es) * 2011-07-20 2017-10-23 Merial Ltd Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
JP6641276B2 (ja) * 2013-11-28 2020-02-05 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
CA3162690A1 (fr) * 2019-12-31 2021-07-08 Minoru S. H. Ko Administration transitoire basee sur la temperature d'acides nucleiques et de proteines a des cellules et des tissus
JP2023508725A (ja) * 2019-12-31 2023-03-03 エリクサージェン セラピューティクス，インコーポレイティド 細胞及び組織へのｚｓｃａｎ４核酸及びタンパク質の温度ベースの一過性送達
CN112143754B (zh) * 2020-09-30 2021-05-18 扬州大学 猪盖塔病毒感染性克隆及其建构方法及应用
WO2023097265A1 (fr) * 2021-11-23 2023-06-01 Wisconsin Alumni Research Foundation Vaccins géniques modifiés dirigés contre des coronavirus aviaires et leurs méthodes d'utilisation
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029279A1 (en) * 2000-08-29 2004-02-12 Kovacs Gerald R. Packaging of positive-strand rna virus replicon particles
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992015672A1 (fr) 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
WO1994017813A1 (fr) 1993-02-08 1994-08-18 Paravax, Inc. VECTEURS DU VIRUS SINDBIS DEFECTIF QUI EXPRIMENT DES ANTIGENES P30 $i(TOXOPLASMA GONDII)
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1998016247A1 (fr) 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
CA2460269C (fr) * 2001-09-06 2013-01-15 Alphavax, Inc. Systemes de vecteurs a base de replicons alphaviraux
WO2004007664A2 (fr) * 2002-05-28 2004-01-22 Maxygen, Inc. Vecteurs d'acides nucleiques
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US20040029279A1 (en) * 2000-08-29 2004-02-12 Kovacs Gerald R. Packaging of positive-strand rna virus replicon particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GANGOLLI ET AL.: "A Method of Alphavirus Replicon Particle Titration Based on Expression of Functional Replicase/Transcriptase", JOURNAL OF VIROLOGICAL METHODS, vol. 109, 2003, pages 133 - 138, XP009048929 *
LORENZO ET AL.: "Intracellular Localization of Vaccinia Virus Extracellular Enveloped Virus Envelope Proteins Individually Expressed Using a Semliki Forest Virus Replicon", JOURNAL OF VIROLOGY, vol. 74, no. 22, November 2000 (2000-11-01), pages 10535 - 10550, XP002460237 *
VASILAKIS ET AL.: "Transfection-Independent Production of Alphavirus Replicon Particles Based on Poxvirus Expression Vectors", NATURE BIOTECHNOLOGY, vol. 21, no. 8, August 2003 (2003-08-01), pages 932 - 935, XP009092814 *

Also Published As

Publication number Publication date
EP1809337B1 (fr) 2017-08-23
BRPI0516576B1 (pt) 2019-09-24
US20060073594A1 (en) 2006-04-06
BRPI0516576A (pt) 2008-09-16
US7998733B2 (en) 2011-08-16
EP1809337A2 (fr) 2007-07-25
CA2583147A1 (fr) 2006-04-20
WO2006041897A2 (fr) 2006-04-20
CA2583147C (fr) 2013-06-25
MX2007004168A (es) 2007-09-11
BRPI0516576B8 (pt) 2021-05-25
BRPI0516576C8 (pt) 2022-06-14
EP1809337A4 (fr) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2006041897A3 (fr) Vecteurs chimériques
WO2009114207A3 (fr) Vaccins de flavivirus défaillant sur le plan de la réplication et vecteurs de vaccin
WO2006133911A3 (fr) Vaccin a base d'acide nucleique contre le virus de l'hepatite c
WO2010120514A3 (fr) Protéines liant des antigènes comprenant des échafaudages protéiniques internes recombinants
WO2005111220A3 (fr) Vecteurs viraux adeno-associes avec des sequences palindromiques terminales heterologues intravectorielles
WO2006044857A3 (fr) Vaccins contre le virus de l'encephalite japonaise et le virus du nil occidental
WO2006096459A3 (fr) Virus infectieux chimeriques de l'hepatite c, leurs procedes de production et leurs methodes d'utilisation
WO2006083276A3 (fr) Polypeptides et conjugues interferon-alpha
WO2004078778A3 (fr) Peptides presentant une fixation specifique avec le recepteur de hgf (cmet) et ses utilisations
WO2004075861A3 (fr) Production de virus recombines adeno associes
WO2005113592A3 (fr) Polypeptides et conjugues interferon-alpha
WO2007049155A3 (fr) Compositions comprenant des antigenes de yersinia pestis
MY173638A (en) Parainfluenza virus 5 based vaccines
WO2009124312A3 (fr) Séquences consensus de protéines du virus chikungunya, molécules d’acide nucléique codant pour celles-ci, et compositions et procédés d’utilisation de celles-ci
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
EP1989316A4 (fr) Méthode de production de virus recombinant, de constructions d'adn et de compositions de vaccin
WO2011091279A3 (fr) Présentation d'antigènes hétérologues ciblés sur des pseudo-particules virales du calicivirus
PL1921146T3 (pl) Rekombinowane wektory oparte na zmodyfikowany wirusie ankara (mva) jako profilaktyczne i terapeutyczne szczepionki przeciw aids
WO2005052143A3 (fr) Adenovirus, acides nucleiques les codant et utilisations associees
WO2009125231A3 (fr) Vaccin anti-athérome
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2006019955A3 (fr) Methodes et compositions antivirales
WO2012040474A3 (fr) Vecteurs viraux recombinants et procédés d'induction d'une réponse immunitaire vis-à-vis du virus de la fièvre jaune
HK1075914A1 (en) Recombinant plasmids expressing two flurorescent genes
WO2006076032A3 (fr) Constructions d'encapsidation de replicon d'alphavirus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2583147

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004168

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2005809870

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005809870

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 07044491

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2005809870

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0516576

Country of ref document: BR